Human equilibrative nucleoside transporter 1 (hENT1) expression is a potential predictive tool for response to gemcitabine in patients with advanced cholangiocarcinoma.

Détails

ID Serval
serval:BIB_F1875384D85C
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Human equilibrative nucleoside transporter 1 (hENT1) expression is a potential predictive tool for response to gemcitabine in patients with advanced cholangiocarcinoma.
Périodique
European Journal of Cancer
Auteur(s)
Borbath I., Verbrugghe L., Lai R., Gigot J.F., Humblet Y., Piessevaux H., Sempoux C.
ISSN
1879-0852 (Electronic)
ISSN-L
0959-8049
Statut éditorial
Publié
Date de publication
2012
Peer-reviewed
Oui
Volume
48
Numéro
7
Pages
990-996
Langue
anglais
Notes
Publication types: Evaluation Studies ; Journal Article Publication Status: ppublish
Résumé
BACKGROUND: Cholangiocarcinoma (CC) is a rare cancer of the liver. Surgery offers the only chance for cure. When surgery is unfeasible, chemotherapy is the backbone of treatment. The combined administration of cisplatin and gemcitabine is considered standard of care. Human equilibrative nucleoside transporter 1 (hENT1) is the major transporter responsible for gemcitabine uptake into cells. hENT1 expression is associated with an increased survival for patients receiving gemcitabine after pancreatic cancer surgery, suggesting that hENT1 is predictive of response to gemcitabine.
AIM: To determine whether there is a correlation between the expression of hENT1 and disease outcome in CC.
METHODS: A retrospective study on 43 patients treated at our centre with a locally advanced or metastatic CC, who received first line treatment with gemcitabine, was performed.
RESULTS: For the whole population, median Progression Free Survival (PFS) and overall survival (OS) were 4.0 (95% Confidence Interval 2.7-5.3 months) and 10.0 months (95%CI 6.8-13.2 months), respectively. From the 26 samples available for hENT1 staining, 18 (69%) and 8 (31%) patients had high and low hENT1 immunostaining, respectively. The median PFS were 2.0 versus 6.0 months for low versus high staining respectively (p = 0.012). The median OS were 5.0 versus 11.0 months for low versus high staining, respectively (p = 0.036). On multivariate analysis, hENT1 expression was the single independent predictive factor associated with prolonged PFS (HR 0.35, p = 0.023) and OS (HR 0.41, p = 0.046).
CONCLUSION: In this study we show the potential of hENT1 expression as a predictor of outcome in CC treated with gemcitabine. Larger studies are necessary to confirm these promising results.
Mots-clé
Adult, Aged, Aged, 80 and over, Antimetabolites, Antineoplastic/therapeutic use, Bile Duct Neoplasms/drug therapy, Bile Duct Neoplasms/metabolism, Cholangiocarcinoma/drug therapy, Cholangiocarcinoma/metabolism, Deoxycytidine/analogs & derivatives, Deoxycytidine/therapeutic use, Disease-Free Survival, Equilibrative Nucleoside Transporter 1/metabolism, Female, Humans, Male, Middle Aged, Predictive Value of Tests, Retrospective Studies, Treatment Outcome
Pubmed
Web of science
Création de la notice
19/01/2015 11:59
Dernière modification de la notice
03/03/2018 22:38
Données d'usage